Skip to main content

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

Publication ,  Journal Article
Nabors, LB; Portnow, J; Ammirati, M; Baehring, J; Brem, H; Butowski, N; Fenstermaker, RA; Forsyth, P; Hattangadi-Gluth, J; Holdhoff, M; Wen, PY ...
Published in: J Natl Compr Canc Netw
November 2017

For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups limited the utility of this system. Nonetheless, histology was the only proven and widely accessible tool available at the time, thus it was used for clinical trial entry criteria, and therefore determined the recommended treatment options. Research to identify molecular changes that underlie glioma progression has led to the discovery of molecular features that have greater diagnostic and prognostic value than histology. Analyses of these molecular markers across populations from randomized clinical trials have shown that some of these markers are also predictive of response to specific types of treatment, which has prompted significant changes to the recommended treatment options for grade III (anaplastic) gliomas.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

November 2017

Volume

15

Issue

11

Start / End Page

1331 / 1345

Location

United States

Related Subject Headings

  • Radiotherapy
  • Prognosis
  • Oncology & Carcinogenesis
  • Nervous System
  • Neoplasm Grading
  • Neoadjuvant Therapy
  • Humans
  • Glioma
  • Combined Modality Therapy
  • Central Nervous System Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nabors, L. B., Portnow, J., Ammirati, M., Baehring, J., Brem, H., Butowski, N., … Engh, A. (2017). NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw, 15(11), 1331–1345. https://doi.org/10.6004/jnccn.2017.0166
Nabors, Louis Burt, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Nicholas Butowski, Robert A. Fenstermaker, et al. “NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.J Natl Compr Canc Netw 15, no. 11 (November 2017): 1331–45. https://doi.org/10.6004/jnccn.2017.0166.
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, et al. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 Nov;15(11):1331–45.
Nabors, Louis Burt, et al. “NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.J Natl Compr Canc Netw, vol. 15, no. 11, Nov. 2017, pp. 1331–45. Pubmed, doi:10.6004/jnccn.2017.0166.
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 Nov;15(11):1331–1345.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

November 2017

Volume

15

Issue

11

Start / End Page

1331 / 1345

Location

United States

Related Subject Headings

  • Radiotherapy
  • Prognosis
  • Oncology & Carcinogenesis
  • Nervous System
  • Neoplasm Grading
  • Neoadjuvant Therapy
  • Humans
  • Glioma
  • Combined Modality Therapy
  • Central Nervous System Neoplasms